COMMUNIQUÉS West-GlobeNewswire

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
23/01/2024
NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial Program developed by Florida Biotechnologies, Inc. & the University of Miami’s [...]
InnovAge to Announce Fiscal Second Quarter 2024 Financial Results and Host Conference Call Tuesday, February 6, 2024
23/01/2024
DENVER, Jan. 23, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application
23/01/2024
MINNEAPOLIS, MN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices [...]
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts
23/01/2024
Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and Profitability Company in Late-Stage Discussions with Two Additional Large Global Brands Which, if [...]
Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million
23/01/2024
Ships more than 60 SRT units in 2023 To report full financial results and hold conference call on February 8 th BOCA RATON, Fla. , Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS ), a medical [...]
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
23/01/2024
4D-710 has demonstrated promising, reproducible, CFTR expression significantly above normal levels for seven patients across Cohorts 1 & 2 (1E15-2E15 vg) and durable improvement or stabilization of quality of life [...]
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
23/01/2024
Obtained clarity from U.S. Food and Drug Administration (FDA) on next steps to advance ONS-5010 NORSE EIGHT expected to commence in the first quarter of CY2024, enabling potential resubmission of the ONS-5010 Biologics [...]
Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
23/01/2024
Bionano has completed the early access program for the Stratys™ system and is now making it available in a full commercial release The Stratys instrument can enable up to a four-fold increase in raw data generation rate [...]
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
23/01/2024
NORWOOD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1 dose escalation study [...]
MedBright AI’s MedMatrix to Expand Its AI Offerings for Cosmetic Marketing & Clinical Trial Analytics
23/01/2024
VANCOUVER, British Columbia, Jan. 23, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright AI”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) is pleased to announce that Rejuvenation, a prominent [...]
IAOMT Position Paper Examines the Science of Jawbone Cavitations Just Ahead of the Yankee Dental Congress!
23/01/2024
LAKELAND, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- The International Academy of Oral Medicine and Toxicology (IAOMT) is pleased to announce the publication of its new position paper on Human Jawbone Cavitations . This [...]
Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy
23/01/2024
ELIMINATE trial is evaluating LBP-EC01 for treating urinary tract infections caused by drug-resistant E. coli Funding to support advancement into Part 2 of ELIMINATE trial RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 ( [...]
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors
23/01/2024
CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Alvin Shih, MD, MBA, to the [...]
iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research
23/01/2024
Partnership Aims to Optimize Quality Control and Assurance Through Digital AI Histopathology Services LEXINGTON, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an [...]
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
23/01/2024
FDA continues to review the file past the Prescription Drug User Fee Act goal date of January 22, 2024 MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH [...]
Theratechnologies reçoit une mise à jour de la FDA concernant son supplément à la licence de produit biologique pour la formulation F8 de la tésamoréline
23/01/2024
La FDA continue d'examiner le dossier après la date butoir du Prescription Drug User Fee Act fixée au 22 janvier 2024 MONTRÉAL, 23 janv. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « [...]
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society
23/01/2024
The presentation will review study population data from ONL’s Phase 2 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE [...]
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
23/01/2024
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and [...]
First Wave BioPharma to Present at the DealFlow MicroCap Conference
23/01/2024
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]

Pages